SEC Comment Letter for Akebia Therapeutics, Inc. (AKBA) (CIK 0001517022) (AKBA) — Apr 24, 2020
Akebia Therapeutics, Inc. (AKBA) (CIK 0001517022)
Date: April 24, 2020 · CIK: 0001517022 · Accession: 0000000000-20-003521
AI Filing Summary & Sentiment
File numbers found in text: 001-36352
Letter
April 24, 2020 John P. Butler Chief Executive Officer Akebia Therapeutics, Inc. 245 First Street Cambridge, MA 02142 Re:Akebia Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 15, 2020 File No. 001-36352 Dear Mr. Butler: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrea Paul, Esq.
Show Raw Text
April 24, 2020
John P. Butler
Chief Executive Officer
Akebia Therapeutics, Inc.
245 First Street
Cambridge, MA 02142
Re:Akebia Therapeutics, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed April 15, 2020
File No. 001-36352
Dear Mr. Butler:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrea Paul, Esq.